Browsing Tag

Landos Biopharma

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus…

Jason Junior Oct 11, 2021

Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its…

Health

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings…

Jason Junior Oct 6, 2021

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients…

Health

Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology…

Jason Junior Sep 15, 2021

Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling Phase 1 clinical trial anticipated to begin…

Health

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

Jason Junior Jun 15, 2021

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for…